Ann: GE Healthcare to Distribute Osprey Medical Technology, page-82

First 82 Last

Share
Profile

Follow
invest

14,434 Posts.

609

30/07/20

09:44

Post #: 46174282
Share

Originally posted by speculativet: ↑

I will be very interested to see how the market receives this announcement. I'm a holder of 9sp and can draw a number of parallels with this deal to 9sp's recent annoucement of a 5 year deal with VISA.

- Both present enormous upside potential for both businesses
- Both were highly telegraphed to the market
- Both provided no specific details as to impact upon future revenues

In the case of 9sp, a pretty signifcant gap opened up pre-trade (circa 70% from memory) as initial fervour set in. The stock opened at around 6.1c and closed the day back down at around 3.5c. Sell-side pressure was intense throughout the day. Ultimately the market seemed to be let down by the lack of details around future revenues.

I see a lot of similarity with the OSP deal with GE. Theres a small gap starting to open up but i would caution anyone looking to jump in on open and watch how it trades throughout the day.

Dont get me wrong - im not down-ramping and think both businesses have signficant potential - but would hate to see people jump in on this announcement and get caught.

GLTA

Expand

I see your point....there are no revenues discussed...its all sales based....so yes it will spike...then lets see how the market reacts during the day. Is it a matter now of sell the news and wait for the sales to roll in next quarter or two....due to covid 19 sales maybe a little way off before the real bucks come in...its a wait and see game..get out the popcorn today

OSP Price at posting: 4.5¢ Sentiment: None Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

IRE

Iress runs 'hot' for Wealth Within's stock tips

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Failure to report prompts ASX to impose multiple company suspensions